Results 231 to 240 of about 421,250 (298)

'Tis the season for cardiometabolic thinking: a Fellow's Voice. [PDF]

Am J Prev Cardiol
Jelwan Y.
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Blood Pressure Polygenic Score Predicts Long-Term Blood Pressure Control and Treatment-Resistant Hypertension. [PDF]

Hypertension
Cho SMJ, Ruan Y, Lee HH, Koyama S, Juraschek SP, Allen NB, Yang E, McEvoy JW, Secemsky E, Honigberg MC, Fahed AC, Patel A, Hornsby WE, Natarajan P.   +13 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity [PDF]

, 2018
Butler, Anne M, et al,
core   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF II. [PDF]

Circ Popul Health Outcomes
Girard AA, Mylavarapu U, Komtebedde J, Arnold SV, Solomon SD, Leon MB, Van Veldhuisen DJ, Cutlip DE, Cikes M, Zile MR, Gustafsson F, Lilly SM, Boyle A, Cleland JGF, Kaye DM, Emani S, Gupta DK, Hoendermis ES, Flaherty JD, Muller DW, Kapadia SR, Herrmann HC, Cohen DJ, Shah SJ, Spertus JA.   +24 more
europepmc   +1 more source

Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.
Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner, Antje Augstein, Mahmoud Abdellatif, André Lourenço, Adelino Leite‐Moreira, Inês Falcão‐Pires, Sarah Werner, Holger Thiele, Simon Sedej, Antje Schauer, Volker Adams   +10 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

The European Program for Prevention (EPP) - Implementing Proven Preventing Measures Now! [PDF]

Glob Heart
Banach M, Fras Z, Gaita D, Pecin I, Bajraktari G, Bjelakovic B, Bytyci I, Ceska R, Djuric D, Gil RJ, Jozwiak J, Kubilius R, Latkovskis G, Mitchenko O, Paragh G, Pella D, Petrulioniene Z, Postadzhiyan A, Stoian AP, Szymański P, Viigimaa M, Vinereanu D, Vohnout B, Vrablik M, Reiner Z, International Lipid Expert Panel (ILEP).   +25 more
europepmc   +1 more source